Yan Lin

7.4k citations
230 papers · 5.5k · 1 hit paper · h-index 38

Impact in

    • MicroRNA in disease regulation
    • Cancer-related molecular mechanisms research
  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research

Papers in

    • RNA modifications and cancer 13
    • RNA Research and Splicing 9
    • Cancer Immunotherapy and Biomarkers 25

Yan Lin

224 papers receiving 5.4k citations

Yan Lin's Hit Papers

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma 2015 · 316 citations
3160+3+7Years since publication100200300

Peers

Yan Lin
Comparison fields: 5 of 146
  • Cancer Research 1.0k
  • Oncology 1.4k
  • Immunology 1.1k
  • Molecular Biology 2.0k
  • Hepatology 185
Replace Anil G. Jegga with:
Anil G. Jegga United States
Álvaro González Spain
Yun Zhang China
Bo Wang China
Wei Chen China
Shan Zeng China
Yan Zhang China
Zhen Zhang China
Chen Wang China
Anton Buzdin Russia
Yan Lin relative to Anil G. Jegga United States Anil G. Jegga's profile →
Citations per field
00.5×1.7×
Anil G. Jegga · 1×
Citations per year

Countries citing papers authored by Yan Lin

Since Specialization
Citations

This map shows the geographic impact of Yan Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Lin more than expected).

Fields of papers citing papers by Yan Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Lin. The network helps show where Yan Lin may publish in the future.

Co-authors

The 25 scholars most cited alongside Yan Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yan Lin Line = papers co-authored together Yan Lin links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 230 papers — load more, or switch the sort, to bring in the rest.

#Work
1 2012404
2
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Hit paper breakdown →
2015316
3 2014245
4 2013174
5 2012168
6 2019164
7 2012128
8 2010114
9 2014111
10 2018102
11 2020102
12 201898
13 200575
14 200865
15 201660
16 201458
17 201956
18 201255
19 201153
20 201353

About Yan Lin

Yan Lin is a scholar working on Molecular Biology, Oncology, Cancer Research, Immunology and Pulmonary and Respiratory Medicine, having authored 230 papers that have together received 5.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (25 papers), Immunotherapy and Immune Responses (17 papers), Cancer-related molecular mechanisms research (13 papers), RNA modifications and cancer (13 papers), MicroRNA in disease regulation (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Pregnancy and preeclampsia studies (9 papers) and RNA Research and Splicing (9 papers). The work is most often cited by research in Cancer Research (1.0k citations), Oncology (1.4k citations), Immunology (1.1k citations), Molecular Biology (2.0k citations) and Hepatology (185 citations). Yan Lin has collaborated with scholars based in China, United States and Japan. Frequent co-authors include John M. Kirkwood, Rong Liang, Ahmad A. Tarhini, Cindy Sander, Lisa H. Butterfield, Jiazhou Ye, Jinyan Zhang, Lianjie Lin, Zhihui Liu and Yongqiang Li. Their work appears in journals such as Journal of Clinical Oncology, Journal of Cancer, Journal for ImmunoTherapy of Cancer, Frontiers in Oncology and OncoTargets and Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact